Abstract

ABO incompatible renal transplantation has gained wide spread acceptance in view of organ shortage. Acceptable Anti A and Anti B titres are achieved by various preconditioning regimens. Some patients have difficulty in achieving target titres due to refractory and rebound isoagglutinin titres. We share our experience with the use of Bortezomib in patients having moderately high base line isoagglutinin titres who had difficulty in achieving target titres during the preconditioning treatment. The use of Bortezomib can possibly reduce the number of plasma exchanges and its attendant complications.

Key words: ABO incompatible transplant, Bortezomib, Antibody titre